U.S. markets open in 3 hours 32 minutes
  • S&P Futures

    4,381.25
    -30.50 (-0.69%)
     
  • Dow Futures

    34,854.00
    -120.00 (-0.34%)
     
  • Nasdaq Futures

    14,870.50
    -167.25 (-1.11%)
     
  • Russell 2000 Futures

    2,226.50
    -11.00 (-0.49%)
     
  • Crude Oil

    73.38
    -0.24 (-0.33%)
     
  • Gold

    1,832.30
    -3.50 (-0.19%)
     
  • Silver

    25.60
    -0.18 (-0.69%)
     
  • EUR/USD

    1.1901
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    19.20
    +0.89 (+4.86%)
     
  • GBP/USD

    1.3971
    +0.0013 (+0.10%)
     
  • USD/JPY

    109.5400
    +0.0790 (+0.07%)
     
  • BTC-USD

    38,728.54
    -1,659.79 (-4.11%)
     
  • CMC Crypto 200

    920.97
    -9.39 (-1.01%)
     
  • FTSE 100

    7,017.12
    -61.30 (-0.87%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Arrowhead Receives $10M Option Exercise Fee From Janssen

·1 min read
  • Janssen Pharmaceuticals Inc, part of Johnson & Johnson (NYSE: JNJ), has delivered written notice of its intent to exercise its option right for ARO-JNJ1.

  • Receipt of the option notice earns Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) a $10 million option exercise fee.

  • Janssen will now have all rights to develop and commercialize ARO-JNJ1, an investigational RNAi therapeutic candidate which utilizes Arrowhead's proprietary Targeted RNAi Molecule platform.

  • "The collaboration with Janssen, which was executed in 2018, for ARO-HBV against chronic hepatitis B infection, and potentially three additional programs, has been highly productive and collaborative," said Chris Anzalone, President & CEO at Arrowhead.

  • Price Action: JNJ shares are down 0.22% at $170.02 during the premarket session on the last check Tuesday. ARWR closed at $73.05 on Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.